| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-12-05 | MNK1 and MNK2 (MNK1/2) kinase inhibitor discovery program | preclinical | Oncodesign (France) | ||
| 2017-12-04 | SAN711 | neuropathic pain, chronic itching | Saniona (Denmark) | ||
| 2017-12-04 | MABp1 (bermekimab) | Hidradenitis Suppurativa | 2 | XBiotech (USA - TX) | Dermatological diseases - Immunological diseases |
| 2017-12-01 | Clostridium difficile vaccine (ACAM-CDIFF™) | prevention of primary symptomatic Clostridium difficile infection |
3 | Sanofi Pasteur (France) | Infectious diseases |
| 2017-11-29 | gMSC®1 | symptomatic articular cartilage defects or osteochondritis dissecans in the knee | 3 | Chugai Pharmaceutical (Japan) Twocells (Japan) | Bone diseases - Regenerative medicine |
| 2017-11-29 | Dysport® (abobotulinumtoxin A ) | 3 | Ipsen (France) | Neurological diseases - Neuromuscular diseases | |
| 2017-11-27 | FYB203 biosimilar version of Eylea® (aflibercept) | neovascular age-related macular degeneration | 1 | Formycon (Germany) Bioeq (Germany) | Ophtalmological diseases |
| 2017-11-27 | PRX-102 (alpha-galactosidase-A) | Fabry disease | 1-2 | Protalix BioTherapeutics (Israel) | Rare diseases - Genetic diseases |
| 2017-11-27 | OPK88004 | benign prostatic hypertrophy | 2b | Opko Health (USA - Fl) | Urological diseases |
| 2017-11-22 | lirilumab or IPH2102/BMS-986015 | acute myeloid leukemia (AML) | 2 | BMS (USA - NY) Innate Pharma (France) | Cancer - Oncology |
| 2017-11-22 | lirilumab or IPH2102/BMS-986015 in combination with nivolumab or Anti-PD-1 (BMS-936558) | advanced refractory solid tumors, advanced platinum refractory squamous cell carcinoma of the head and neck (SCCHN) | 1-2 | BMS (USA - NY) Innate Pharma (France) | Cancer - Oncology |
| 2017-11-21 | X-linked myotubular myopathy (XLMTM) | Audentes Therapeutics (USA - CA) | Rare diseases - Genetic diseases - Neuromuscular diseases | ||
| 2017-11-20 | TAL nucleases (TALEN®) targeting PD1 | Cellectis (France) | Cancer - Oncology | ||
| 2017-11-20 | emicizumab (ACE910 - anti-factor IXa x anti-factor X humanized bispecific antibody) | hemophilia A | 3 | Roche (Switzerland) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-11-16 | LentiGlobin® BB305 (autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) | transfusion-dependent beta-thalassemia | 3 | Bluebird bio (USA - MA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-11-15 | ALK1 kinase inhibitor discovery program | preclinical | Oncodesign (France) | Cancer - Oncology | |
| 2017-11-15 | afatinib in first-line, followed by second-line osimertinib | EGFR mutation-positive (M+) advanced non-small cell lung cancer (NSCLC) | Boehringer Ingelheim (Germany) | Cancer - Oncology | |
| 2017-11-14 | TPIV 200 (multi-epitope folate receptor alpha peptide vaccine with GM-CSF adjuvant) | triple-negative breast cancer (TNBC) | 2 | Tapimmune (USA - FL) | Cancer - Oncology |
| 2017-11-13 | NKTR-214 and great apes adenoviral vaccine encoding neoantigens | preclinical | Nouscom (Switzerland) Nektar Therapeutics (USA - CA) | Cancer - Oncology | |
| 2017-11-12 | tabelecleucel (formerly known as ATA129) | EBV associated cancers | Atara Biotherapeutics (USA - CA) | Cancer - Oncology |
